Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
inhibits ALK and RO S1 tyrosine kinases
|
| gptkbp:approves |
gptkb:2011
gptkb:FDA |
| gptkbp:class |
tyrosine kinase inhibitor
|
| gptkbp:clinical_trial |
Phase 1
combination therapy Phase 2 Phase 3 monotherapy |
| gptkbp:contraindication |
severe liver impairment
hypersensitivity to crizotinib |
| gptkbp:dosage_form |
gptkb:beer
|
| gptkbp:formulation |
oral capsule
|
| gptkbp:has_ability |
200 mg
250 mg |
| https://www.w3.org/2000/01/rdf-schema#label |
Xalkori
|
| gptkbp:ingredients |
gptkb:crizotinib
C21 H22 Cl2 N4 O2 S |
| gptkbp:interacts_with |
gptkb:warfarin
CY P3 A4 inducers CY P3 A4 inhibitors |
| gptkbp:invention |
2027
|
| gptkbp:is_monitored_by |
liver function tests
vision tests QT interval |
| gptkbp:is_used_for |
treatment of non-small cell lung cancer
|
| gptkbp:label |
prescribing information
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:marketed_as |
gptkb:Xalkori
|
| gptkbp:packaging |
gptkb:beer
|
| gptkbp:population |
adults
pediatric patients |
| gptkbp:research_areas |
clinical trials
oncology pharmacology |
| gptkbp:side_effect |
gptkb:fandom
dizziness fatigue headache nausea vomiting vision problems diarrhea rash constipation thrombocytopenia neutropenia pneumonitis liver problems peripheral edema |
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
gptkb:ALK_gene_rearrangements
RO S1 gene rearrangements |
| gptkbp:bfsParent |
gptkb:crizotinib
gptkb:Crizotinib |
| gptkbp:bfsLayer |
6
|